[link removed]
[link removed] [link removed]
View web version ([link removed])
[link removed]
Drug company insiders are profiting handsomely from world’s desperate hope for a COVID-19 vaccine
Insiders at companies developing COVID-19 vaccines and treatments aren’t waiting until they finish the job to collect their reward. Executives, board members, and related investment funds have made fortunes from the rise in their companies' stock prices before a single vaccine has proven safe or a game-changing treatment has been approved.

Since March, these insiders at a dozen companies have sold more than $1.3 billion in stock, up from just $74 million in the same period last year, according to information compiled by Equilar, a data provider based in Redwood City, Calif., and analyzed by the Globe.

Read the full story at BostonGlobe.com. ([link removed])

------------------------------------------------------------
We have lots of e-mail newsletters on a variety of topics, including news, politics, business, sports, lifestyle, and more. They're free, and it's easy to subscribe. Here's a complete list. ([link removed])
------------------------------------------------------------
[link removed]
[link removed] [link removed]

============================================================
** Like us ([link removed])
** Follow us ([link removed])
You received this message because you signed up for Breaking News Alerts.

Copyright © 2020 The Boston Globe, All rights reserved.

Our mailing address is:
The Boston Globe
1 Exchange Place Suite 201
Boston, MA 02109-2132
USA

** unsubscribe from this list ([link removed])

** Manage Your Account ([link removed])
| ** Terms of Service ([link removed])
| ** Privacy Policy ([link removed])
| ** Help Center ([link removed])
| ** Advertise (mailto:[email protected]?subject=Advertising+in+BostonGlobe.com)